 Genotyping platforms such as MALDI-TOF mass spectrometry allow for precise and sensitive detection of fetal-specific paternally derived alleles in maternal plasma. In this study, Sequenoms MassARRAY technology will be used to assess a noninvasive test for fetal RHD genotyping in a clinical setting. 